Skip to main content

EU Court Asks EFSA To Reveal Glyphosate Cancer Studies

EU Court Asks EFSA To Reveal Glyphosate Cancer Studies

EU Court Asks EFSA To Reveal Glyphosate Cancer Studies

Introduction

On Thursday, EU court ruled that the European Food Safety Agency (EFSA) must disclose to European lawmakers the details of studies about the dangers and carcinogenic nature of glyphosate in support of the campaigners who want Roundup weedkiller banned.

In the statement released, the European Court of Justice’s General Court told that the intent was to give the general public access to the research information, along with the knowledge of what is or could be released into the environment and understand the severity of that release. Judges recalled two decisions by EFSA that denied access to the research details. Green members of the European Parliament brought the two cases. The agency's spokesperson told, "EFSA welcomes the decision. This case, and the Court’s ruling is important because it provides orientation for EFSA and others charged with interpreting EU legislation on public access to documents." Monsanto sold glyphosate-containing herbicide under the brand name Roundup. Presently, it is off-patent and marketed by dozens of other distributors including Dow AgroSciences and Germany’s BASF. In 2015, a World Health Organization agency raised concerns about glyphosate's safety and effectiveness while concluding that it was a probable reason for cancer in humans.

Roundup bellwether trials are currently underway in the Northern District of California, where  Judge Vince Chhabria overlooks the multidistrict litigation (MDL No. 2741; In re: Roundup Products Liability Litigation).

Comments

Restricted HTML

  • Allowed HTML tags: <a href hreflang> <em> <strong> <cite> <blockquote cite> <code> <ul type> <ol start type> <li> <dl> <dt> <dd> <h2 id> <h3 id> <h4 id> <h5 id> <h6 id>
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.

Latest News

Cencora Directors Settle Opioid Oversight Case for $111M

Categories: Opioids

Cencora has agreed to pay $111.3 million to settle a shareholder lawsuit accusing the company’s directors of failing to prevent the unlawful distribution of opioids

Study Finds CPAP May Harm Low-Risk Sleep Apnea Patients

A new study has cast doubt on the long-standing belief that continuous positive airway pressure (CPAP) machines significantly reduce heart…

FDA Adds New Warnings on Long-Term Opioid Risks

Categories: Opioids

Federal regulators have raised concerns that many opioid medications were approved for prolonged use without sufficient clinical evidence confirming their safety.

✍️ FREE — 2,800 Pages Legal Process Outsourcing Trial!                 
No Contract. No Risk — Full Mass Tort + LPO Access, Free!

Only 10 Firms Accepted—Offer Ends August 31!